UBS initiated coverage of Option Care Health (OPCH) with a Neutral rating and $26 price target While there are some fundamental tailwinds for the company, there is also “unusual uncertainty” regarding the financial implications related to Stelara, a large specialty drug slated to undergo significant changes in 2025, the analyst tells investors in a research note. The firm has trouble gaining comfort around Option Care’s ability to achieve its stated growth algorithm over the near to intermediate-term.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPCH:
- Option Care Health management to meet with Truist
- Roblox, Peloton upgraded: Wall Street’s top analyst calls
- Option Care Health downgraded to Neutral at Goldman on Stelara headwinds
- Option Care Health downgraded to Neutral from Buy at Goldman Sachs
- Option Care Health price target lowered to $34 from $41 at Truist